LFG
LCTX icon

Larson Financial Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Larson Financial Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197 Hold
150
– – ﹤0.01% 3606
2026
Q1 		$237 Hold
150
– – ﹤0.01% 3428
2025
Q4 		$251 Buy
+150
New +$260 ﹤0.01% 3246
2025
Q2 		– Sell
-10,000
Closed -$4.52K – 3403
2025
Q1 		$4.52K Buy
+10,000
New +$5.87K ﹤0.01% 1911

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Larson Financial Group's LCTX Position: Q2 2026 in Review

Larson Financial Group held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 150 shares worth $197. The position accounts for ﹤0.01% of the portfolio, ranked #3606.

Larson Financial Group first reported a position in LCTX in Q1 2025 and has held it in 4 quarters since. The position peaked at $4.52K in Q1 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Larson Financial Group held 150 shares of Lineage Cell Therapeutics worth $197 as of Q2 2026.
  • Larson Financial Group left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3606 holding.
  • Larson Financial Group first reported a position in Lineage Cell Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Larson Financial Group's Lineage Cell Therapeutics position peaked at $4.52K in Q1 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.